Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In Vivo
Viruses · 31.05.2025 · 17 (6) · 802
DOI: 10.3390/v17060802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 31.05.2025. Verfasst von Ariana Arduini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada. Hauptthemen laut MEDLINE: Lentivirus, Genetic Vectors, Genetic Therapy, Gene Transfer Techniques. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 187 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research (CIHR), CIHR Catalyst Grant, Canada Graduate Scholarships—Doctoral program (CGS-D) award.
Abstract (Originalsprache)
Lentiviral vectors (LVs) have become a fundamental tool in gene therapy due to their unique ability to transduce both dividing and non-dividing cells, transfer large genes of up to 10 kb, and facilitate stable, long-term expression of therapeutic genes into target cells. A key application of LVs is the ex vivo genetic modification of patient-derived cells, such as the production of CAR-T cells by transducing isolated T cells with LVs to express the CAR gene, enabling them to target and destroy cancer cells once infused back into the patient. However, these ex vivo gene therapy drugs are often dismally unaffordable due to the complex procedures involved, including cell isolation, genetic modification, and expansion, along with the significant risks associated with immune conditioning to ensure successful engraftment. To overcome these barriers, direct in vivo transgene delivery to physiologically relevant cells has been explored, bypassing the need for ex vivo manipulations and reducing costs. Yet, a major challenge in this approach is engineering LV cell tropism to ensure the precise targeting of specific cells while avoiding off-target effects. Recent advances in modifying LV surface proteins have shown promise, including the successful in vivo generation of CAR T cells and ensuing clinical trials. This review is aimed at providing an up-to-date account of the progress in engineering LV tropism, covering the utility of different heterologous viral envelopes and their engineering to achieve cell-type-specific delivery and host immune evasion, and highlighting the potential of in vivo gene therapy to improve the affordability and accessibility of life-saving treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Lady Davis Institute, Jewish General Hospital, Montreal, QC H3T 1E2, Canada.
- Department of Medicine, McGill University, Montreal, QC H3G 2M1, Canada.
- Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
Förderung
- Canadian Institutes of Health Research (CIHR)
- CIHR Catalyst Grant
- Canada Graduate Scholarships—Doctoral program (CGS-D) award
Zitieren
APA
Arduini, A., Katiyar, H., & Liang, C. (2025). Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In Vivo. Viruses, 17(6), 802. https://doi.org/10.3390/v17060802
Vancouver
Arduini A, Katiyar H, Liang C. Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In Vivo. Viruses. 2025;17(6):802. doi:10.3390/v17060802
BibTeX
@article{Arduini2025,
author = {Arduini, Ariana and Katiyar, Harshita and Liang, Chen},
title = {Progress in Pseudotyping Lentiviral Vectors Towards Cell-Specific Gene Delivery In Vivo},
journal = {Viruses},
year = {2025},
volume = {17},
number = {6},
pages = {802},
doi = {10.3390/v17060802}
}
EUVIMED